Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

NCT00662649 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

920

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Fingolimod 0.5 mg
DRUG: Fingolimod 1.25 mg

Sponsor

Novartis